



**Internationally Renowned Brain Cancer Expert
Professor Donald M. O'Rourke, MD of Penn
Joins Prescient Scientific Advisory Board**

MELBOURNE Australia, 19 August 2021 – Prescient Therapeutics (ASX: PTX), a clinical stage oncology company developing personalised therapies to treat cancer, today announced the appointment of global authority on brain cancer, Donald M. O'Rourke, MD, to its Scientific Advisory Board (SAB). Professor O'Rourke's renowned expertise in glioblastoma multiforme (GBM), the most aggressive form of brain cancer, will be especially valuable in the development of Prescient's OmniCAR GBM program, where the unique features of OmniCAR aim to overcome obstacles that have limited the success of other GBM CAR-T therapies.

Professor O'Rourke is a tenured Professor in the department of Neurosurgery in the Perelman School of Medicine at the University of Pennsylvania (Penn) and the Abramson Cancer Center and holds the John Templeton, Jr., MD Endowed Chair in Neurosurgery. He is Director of the GBM Translational Center of Excellence in Penn's Abramson Cancer Center and has extensively studied therapies for the treatment of GBM.

Amongst Professor O'Rourke's many achievements in GBM research is leading the Penn group in the first-in-human clinical trial using CAR-T cells for treatment of recurrent GBM and recently completing a clinical trial for newly diagnosed glioblastoma patients, utilizing a combination of CAR-T cells and PD-1 inhibition.

Professor O'Rourke said, "I am delighted to be appointed to Prescient's SAB to help bring promising new therapies to cancer patients. GBM is a particularly insidious disease that is very hard to treat. CAR-T therapy holds promise for treating GBM, but must overcome several unique challenges that the disease presents. I am especially excited to see how OmniCAR's control and ability to target multiple cancer antigens can address these challenges in GBM."

Prescient Managing Director and CEO Steven Yatomi-Clarke said, "Prescient is delighted to welcome an expert of Professor O'Rourke's international standing to its SAB. His expertise – both as clinician and research leader – will be invaluable as the Company progresses our pipeline of cancer treatments."



“In particular, Professor O’Rourke’s insights and expertise in CAR-T treatments for GBM are unsurpassed, and will help guide the OmniCAR GBM program through the challenges that other approaches have encountered.”

Professor O’Rourke joins CAR-T expert, Professor Phil Darcy and renowned hematologist and researcher Professor H. Miles Prince, AM, on Prescient’s SAB.

- Ends -

More about Professor Donald M. O’Rourke, MD

Donald M. O’Rourke, MD, holds the John Templeton, Jr., MD Endowed Chair in Neurosurgery, and is Professor (with *tenure*) in the Department of Neurosurgery and The Abramson Cancer Center at the Perelman School of Medicine, University of Pennsylvania.

Dr. O’Rourke is the Director of the Glioblastoma Translational Center of Excellence (TCE) in the Abramson Cancer Center as well as the Director of the Human Brain Tumor Tissue Bank.

He is a founding member of the Philadelphia Coalition for a Cure (PC4C), a first-of-its-kind precision medicine study supporting collaborative research on brain tumors across both pediatric and adult patients.

Dr. O’Rourke’s laboratory studies EGFR targeted therapies and immunotherapies for brain cancer, including the application of Chimeric Antigen Receptor T-Cell (CART) immunotherapy to glioblastoma.

After graduating from Harvard College *magna cum laude* (Biochemistry and Molecular Biology), Dr. O’Rourke received his MD from the University of Pennsylvania School of Medicine and completed his residency in Neurosurgery and fellowship in Pathology & Laboratory Medicine at the Hospital of the University of Pennsylvania and the School of Medicine.

He has been recognized annually in *Philadelphia Magazine’s* list of Top Doctors since 2005, and has also been named one of the Best Doctors in America and one of America’s Top Doctors annually since in 2006.

Join a briefing

Managing Director and CEO Steven Yatomi-Clarke will be holding an investor briefing on Wednesday 25th August at 11am (AEST). [Click here to register for the briefing.](#)

To stay updated with the latest company news and announcements, [please update your details](#) on our investor centre.



About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Cell Therapies

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post- translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Prescient is developing OmniCAR programs for next-generation CAR-T therapies for Acute Myeloid Leukemia (AML); Her2+ solid tumours, including breast, ovarian and gastric cancers; and glioblastoma multiforme (GBM).

Cell Therapy Enhancements: Prescient has several other initiatives underway to develop new cell therapy approaches.

Targeted Therapies

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX- 100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas.

PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition, PTX-200 has a novel mechanism of action that specifically inhibits Akt without non-specific kinase inhibition effects. This highly promising compound has previously generated encouraging Phase 2a data in HER2-negative breast cancer and Phase 1b in recurrent or persistent platinum resistant ovarian cancer, with a Phase 1b/2 trial currently underway in relapsed and refractory AML.

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

Find out more at www.ptxtherapeutics.com or connect with us via Twitter [@PTX_AUS](https://twitter.com/PTX_AUS) and [LinkedIn](https://www.linkedin.com/company/ptxtherapeutics).

Steven Yatomi-Clarke

CEO & Managing Director

Prescient Therapeutics

steven@ptxtherapeutics.com

Investor enquiries:

Warrick Lace – Reach Markets

+61 404 656 408

warrick.lace@reachmarkets.com.au

Media enquiries:

Andrew Geddes – CityPR

+61 2 9267 4511

ageddes@citypublicrelations.com.au



Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Supplemental COVID-19 Risk Factors

Please see our website : [Supplemental COVID-19 Risk Factors](#)